

TABLE OF CONTENTS

0. Executive Summary	17
1. Basic Aspects of Pain	19
Introduction.....	19
Historical aspects of pain	19
Pain definitions	21
A glossary of terms relevant to pain	22
Pain classification and description	22
Neuropathic pain.....	23
Cancer pain.....	25
<i>Bone pain in cancer.....</i>	<i>27</i>
Complex regional pain syndrome	27
Mechanisms of pain	28
Pain pathways	28
<i>Role of nociceptors in pain transmission.....</i>	<i>29</i>
Gate control and neuromatrix theories of pain	30
Pain mediators.....	31
Modulation of pain by pictures associated with social contacts	31
Modulation of pain by emotions	31
Role of the sympathetic nervous system in pain.....	32
Visceral pain.....	32
<i>Pathomechanism of visceral pain.....</i>	<i>32</i>
Pathomechanism of neuropathic pain.....	33
<i>Role of intact nerve fibers in neuropathic pain</i>	<i>33</i>
<i>Chemokines as mediators of neuropathic pain</i>	<i>33</i>
<i>Chemotherapy-induced neuropathic pain</i>	<i>34</i>
<i>CNS innate immunity and neuropathic pain</i>	<i>34</i>
<i>Cytokines as mediators of neuropathic pain.....</i>	<i>34</i>
<i>Free radicals in generation of neuropathic pain</i>	<i>34</i>
<i>Genetic basis of neuropathic pain.....</i>	<i>35</i>
<i>Gene expression changes in neuropathic pain.....</i>	<i>35</i>
<i>Glial activation and neuropathic pain</i>	<i>36</i>
<i>Immune cell-derived opioids and neuropathic pain</i>	<i>36</i>
<i>Spinal leptin and neuropathic pain.....</i>	<i>36</i>
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity</i>	<i>37</i>
Pathomechanism of migraine.....	37
Role of the immune system in pain	38
Pain and itch	38
<i>Pathomechanism of itch.....</i>	<i>38</i>
<i>Clinical aspects of itch</i>	<i>39</i>
Molecular pathophysiology of pain.....	39
Role of ion channels in pain.....	39
<i>Acid-sensing ion channels</i>	<i>40</i>
<i>Calcium channels in pain.....</i>	<i>40</i>
<i>P2X3 ion channels.....</i>	<i>41</i>
<i>Potassium ion channels.....</i>	<i>41</i>
<i>Sodium ion channels in pain</i>	<i>42</i>
<i>TRP ion channels in pain</i>	<i>43</i>
Genetic basis of pain	43
<i>Study of genes in pain.....</i>	<i>44</i>
<i>Pain as a channelopathy</i>	<i>45</i>
Pain in the brain	45
<i>Neuropathic pain-induced morphological changes in the brain.....</i>	<i>46</i>
Change from acute to chronic pain	46
<i>Descending facilitatory modulation of pain</i>	<i>46</i>
<i>Development of chronic pain following severe accidental injury.....</i>	<i>47</i>
<i>Pain and transcriptional repressor DREAM</i>	<i>47</i>
<i>Role of neuronal plasticity in pain.....</i>	<i>47</i>
Neurochemistry of pain.....	48
<i>Molecular elements of pain in the peripheral nervous system.....</i>	<i>48</i>
<i>Molecular elements of pain in the central nervous system</i>	<i>49</i>
<i>Opioid receptors</i>	<i>49</i>
<i>Role of AMPA receptors in chronic pain</i>	<i>50</i>
<i>Kinins.....</i>	<i>50</i>
<i>Serotonin</i>	<i>50</i>
<i>Substance P</i>	<i>51</i>
<i>Excitatory amino acids.....</i>	<i>51</i>
<i>Role of nitric oxide in pain.....</i>	<i>51</i>

<i>Prostaglandins</i>	52
<i>Endocannabinoids</i>	53
<i>Protein kinase C</i>	53
<i>Adenosine and adenosine receptors</i>	53
<i>Vitamin D and pain</i>	53
<i>Vanilloid receptor</i>	54
<i>TRPA₁ and TRPV₁ receptors</i>	54
<i>Endothelin-B receptors</i>	55
<i>Nerve growth factor and pain</i>	55
<i>Adrenomedullin as a pain-related peptide</i>	56
Biomarkers of pain	56
<i>Biomarkers of visceral pain</i>	56
2. Assessment of Pain and Analgesics	59
Introduction.....	59
Animal models of pain	59
An overview	59
Selection of animal species as models for pain.....	59
Types of noxious stimuli	60
Animal models of neuropathic pain.....	60
Animal models of arthritis	60
Animal models of peripheral neuropathy	61
Limitations of current pain models	61
Biogenic animal model of chronic pain	62
Ethical issues concerning animal pain models	62
Medical evaluation of pain	63
Chronic pain as a manifestation of various diseases.....	63
Assessment of pain patients	63
Medical examination	63
Measurement of pain	64
Quantitative sensory testing.....	65
Pain measurement tools for neonates and children	66
Quantitative sensory testing	66
Psychological assessment of pain	67
Brain imaging in pain.....	67
<i>PET for study of pain</i>	67
<i>PET correlated with fMRI and evoked potentials</i>	68
Patient outcomes and quality of life during treatment for chronic pain	68
Collection and analysis of data on pain patients	69
Evaluation of analgesics in humans	69
Early phase clinical trials of analgesics in humans	69
Design of clinical trials for pain	70
Assessment of neuropathic pain.....	71
Transdermal electrical stimulation for study of chronic pain	71
Placebo effect in pain	72
Role of electronic pain recording in determination of the placebo effect.....	72
Outcome measures for chronic pain trials.....	73
Pain, pain therapies and cognitive function	73
3. Pharmacotherapy of Pain.....	75
Introduction.....	75
Mechanism of action of currently used pain medications	75
Non-steroidal antiinflammatory drugs	76
COX-2 inhibitors	76
<i>Celecoxib</i>	77
<i>Metamizole</i>	78
<i>Nimesulide</i>	78
<i>Rofecoxib</i>	78
<i>Valdecoxib</i>	79
<i>Lumiracoxib</i>	79
<i>Side effects of COX inhibitors</i>	80
<i>Innovative COX-2 inhibitors in development</i>	81
Acetaminophen.....	82
Antioxidants as analgesics	82
Opiates and opioids	83
Innovations in opioid therapy	83
<i>Oral transmucosal fentanyl</i>	84
<i>Use of opioids for chronic non-cancer pain</i>	84
Opioid receptor modulation for visceral pain	84
Opiorphin.....	85
N-methyl-D-aspartate receptor antagonists	85

Ketamine	85
CNS 5161	86
Triptans for treatment of non-migrainous pain	86
Capsaicin	86
NGX-4010	87
Local anesthetics	87
Topical application	87
Nerve blocks	87
<i>Injection of local anesthetics for analgesia</i>	<i>88</i>
<i>Ultrasound-guided nerve blocks</i>	<i>88</i>
Topical salicylates for the treatment of pain	88
Topical rubefacients for acute and chronic pain in adults	88
Adjunctive analgesics	89
Antidepressants	89
<i>Mechanism of analgesic action of antidepressants</i>	<i>90</i>
Antiepileptic drugs	91
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	<i>91</i>
Carbamazepine	92
Gabapentin	92
Lamotrigine	93
Phenytoin	93
Pregabalin	94
Topiramate	95
Valproic acid	95
Other antiepileptic drugs	95
Clonidine	95
Baclofen	96
Corticosteroids	96
Calcitonin	97
Bisphosphonates	97
Botulinum toxins	97
Analgesic effect of botulinum toxin A	98
Engineered botulinum toxin	98
Analgesics from traditional medical systems	98
Herbs and other plants	99
Analgesics derived from cobra toxin	100
Adverse effects of analgesics	100
Gastrointestinal adverse effects of NSAIDs	100
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs</i>	<i>100</i>
Cardiovascular adverse effects of COX-2 inhibitors	100
Adverse effects of opioids	101
<i>Risk of addiction and development of tolerance</i>	<i>101</i>
<i>Companies developing products to deter abuse of opioids</i>	<i>101</i>
<i>Remoxy versus Oxycontin</i>	<i>102</i>
<i>Hyperalgesia associated with opioids</i>	<i>102</i>
<i>Respiratory depression</i>	<i>103</i>
<i>Opioid-associated constipation</i>	<i>103</i>
<i>Narcotic bowel syndrome</i>	<i>103</i>
Adverse effects of use of opioids in non-malignant pain	103
Approaches to reduce adverse effects of opioids	104
<i>PEGylated naloxol</i>	<i>104</i>
<i>Innovative approaches to modify opioid pharmacology</i>	<i>104</i>
<i>Regulatory aspects of opioid abuse, overdose and death</i>	<i>104</i>
Adverse effects of miscellaneous non-narcotic analgesics	105
<i>Adverse effects of immunosuppressants used for relief of pain</i>	<i>105</i>
<i>Adverse effects of acetaminophen</i>	<i>106</i>
4. Management of Pain	107
Introduction	107
Sites for pain management	107
Self-medication at home	107
Physicians' offices	107
Major hospitals	107
Pain centers	108
Non-pharmacological approaches to pain	108
Alternative medicine	108
<i>Acupuncture</i>	<i>109</i>
<i>Aromatherapy</i>	<i>109</i>
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	<i>110</i>
Behavioral therapy	110
<i>Cognition and pain</i>	<i>110</i>

<i>Control over brain activation and pain by using functional MRI</i>	110
<i>Thermal-grill illusion</i>	111
<i>Virtual reality therapy</i>	111
Local application of heat	111
Transcutaneous nerve stimulation	112
Transcranial magnetic stimulation	112
Neurosurgery for pain relief.....	112
<i>Ablative procedures on the nervous system</i>	113
<i>Procedures on peripheral, spinal and cranial nerves</i>	113
<i>Vagal nerve stimulation for control of pain</i>	113
<i>Neuromodulation</i>	113
<i>Spinal cord stimulation</i>	114
<i>Brain stimulation</i>	115
<i>Implantation of drug delivery devices</i>	115
Management of special types of pain	115
Acute pain.....	115
<i>Management of acute renal colic: NSAIDs vs. opioids</i>	115
<i>Combination of opioids and NSAIDs for acute pain</i>	116
<i>Reasons for inadequate management of acute pain</i>	116
Perioperative pain management.....	116
<i>Devices for delivery of analgesics in the postoperative period</i>	117
<i>Drug combination for perioperative pain</i>	118
<i>Gabapentin for reduction of postoperative pain</i>	118
<i>Ketamine for perioperative pain</i>	118
<i>Opioids for perioperative pain</i>	119
<i>Perioperative pain in neurosurgery</i>	119
<i>Prolonged duration local anesthesia</i>	119
<i>Concluding remarks on the management of postoperative pain</i>	120
Pain in the intensive care unit.....	120
Pain associated with sports and exercise	121
Pain associated with trauma	121
Chronic abdominal pain	122
Functional somatic syndromes	122
Fibromyalgia syndrome.....	122
<i>Pathomechanism of FMS</i>	123
<i>Management of FMS</i>	123
<i>New developments in pharmacotherapy of FMS</i>	124
Erythromelalgia	125
Irritable bowel syndrome	125
<i>Opioids for IBS</i>	126
<i>Tricyclic antidepressants for IBS</i>	126
<i>Serotonin-modulating drugs for IBS</i>	127
Musculoskeletal pain.....	127
Myofascial pain syndrome	127
Osteoarthritis	128
<i>Pathomechanism of osteoarthritis</i>	128
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	129
<i>Management of osteoarthritis</i>	129
Rheumatoid arthritis.....	130
<i>Management of pain in rheumatoid arthritis</i>	131
<i>Disease modifying therapies in rheumatoid arthritis</i>	131
<i>Resurgence of interest in gold-based treatments for RA</i>	132
Backache	132
<i>Use of analgesics for management of back pain</i>	133
<i>Miscellaneous medical therapies for backache and sciatica</i>	134
Neck pain.....	134
Chronic pelvic pain	135
<i>Prostatitis</i>	135
Cancer pain.....	135
<i>Opioid treatment of cancer pain</i>	136
<i>Breakthrough and opioid-insensitive pains</i>	137
<i>Morphine-induced enhancement of cancer growth and its prevention</i>	137
<i>Methods of delivery of opioids for cancer pain</i>	138
<i>Implantation of drug delivery devices</i>	138
<i>Management of bone pain in cancer</i>	139
<i>Use of non-opioid analgesics for cancer pain</i>	139
<i>Adjuvant drugs for cancer pain</i>	140
<i>Radiation therapy</i>	140
<i>Alternative non-pharmacological methods</i>	140
<i>Anesthetic techniques</i>	140
<i>Surgical methods of cancer pain relief</i>	140

<i>Conclusions regarding management of cancer pain</i>	141
Chronic non-malignant pain.....	141
Headache.....	142
<i>Migraine</i>	142
<i>Management of acute migraine</i>	143
<i>Neurostimulation for migraine</i>	147
<i>Transcranial magnetic stimulation for migraine</i>	148
<i>Migraine prophylaxis</i>	148
<i>Cluster headache</i>	149
<i>Paroxysmal hemicrania</i>	149
<i>Tension headache</i>	149
<i>Chronic daily headache</i>	150
Trigeminal neuralgia.....	150
Dental pain.....	151
Neuropathic pain.....	151
<i>Pathogenesis of neuropathic pain</i>	151
<i>Chronobiology of neuropathic pain as guide to therapy</i>	152
<i>Management of neuropathic pain based on mechanism</i>	153
<i>Guidelines for the management of neuropathic pain</i>	153
<i>Pharmacotherapy of neuropathic pain</i>	153
<i>Evidence-based management of neuropathic pain</i>	156
Management of central neuropathic pain.....	156
<i>Neurosurgical approaches to central neuropathic pain</i>	156
<i>Management of neuropathic pain in syringomyelia</i>	157
<i>Neuropathic pain associated with spinal cord injury</i>	157
Peripheral neuropathic pain.....	158
<i>Management of postsurgical peripheral neuropathic pain</i>	158
<i>Management of chemotherapy-induced pain</i>	158
<i>Morton's neuroma</i>	159
<i>Management of peripheral diabetic neuropathy</i>	159
<i>Postherpetic neuralgia</i>	161
<i>Complex regional pain syndrome</i>	163
<i>An algorithm for the management of peripheral neuropathic pain</i>	164
Phantom limb pain.....	165
<i>Pathomechanism of phantom limb pain</i>	165
<i>Management of phantom limb pain</i>	165
Pain and depression.....	167
<i>Neurochemical link between pain and depression</i>	168
<i>Management of chronic pain and depression</i>	168
Miscellaneous painful conditions.....	169
<i>Burning mouth syndrome</i>	169
<i>Chronic unstable angina</i>	170
<i>Mastalgia</i>	170
<i>Ophthalmic pain</i>	170
<i>Pain in Parkinson's disease</i>	171
Management of chronic unexplained pain.....	171
Management of itching.....	171
<i>Topical applications for itching</i>	172
<i>Systemic therapies for itching</i>	173
<i>Non-pharmacological therapies for itch</i>	174
Management of pain in special population groups	174
Racial and ethnic differences in pain management.....	174
Pain in neonates.....	174
Management of pain in children.....	175
Management of pain in the elderly.....	175
Management of pain in women.....	177
<i>Reasons for increased pain perception in women</i>	177
<i>Chronic pelvic pain in women</i>	177
<i>Gender differences in response to analgesics</i>	177
<i>Considerations for pain management in women</i>	178
Management of pain in neurologically handicapped persons.....	178
Management of pain in the cognitively impaired elderly people.....	179
Management of pain in brain-damaged minimally conscious patients.....	179
Management of pain in the terminally ill.....	180
Deficiencies in the management of pain	180
Negative physician attitudes in pain management.....	181
Suggestions for improvement of pain management by healthcare providers.....	181
Pain as the fifth vital sign.....	183
Management of neuropathic pain in patients refractory to first line treatment.....	183
Multidisciplinary approaches to pain management	183

5. Drug Delivery for Pain	185
Introduction.....	185
Intra-articular injection for relief of joint pain.....	186
Controlled release drug delivery for pain	186
Accelerating the effect of subcutaneous morphine	186
Controlled drug delivery at site of pain	186
Oral extended release opioids.....	187
<i>Extended release oral morphine</i>	<i>187</i>
<i>Controlled release oxycodone</i>	<i>188</i>
<i>Extended release oxymorphone</i>	<i>188</i>
<i>Oral extended release tramadol</i>	<i>188</i>
Extended release gabapentin.....	189
Use of nanotechnology for drug delivery for pain.....	189
Non-injection methods of delivery of analgesics.....	189
Topical applications for pain	190
<i>Topical local anesthetics.....</i>	<i>190</i>
<i>Topical NSAIDs</i>	<i>190</i>
<i>Topical and transdermal diclofenac.....</i>	<i>191</i>
<i>Topical application for postoperative pain</i>	<i>191</i>
Needle-free drug delivery for pain.....	192
<i>Glide SDI® solid dose injector</i>	<i>192</i>
<i>SUMAVEL™ DosePro™ needle-less injection.....</i>	<i>192</i>
Transdermal drug delivery for pain.....	192
<i>Relief of pain associated with minor medical procedures</i>	<i>192</i>
<i>Transdermal fentanyl.....</i>	<i>193</i>
<i>Transdermal ketoprofen</i>	<i>194</i>
<i>Transdermal nitroglycerine as an adjuvant to opioids.....</i>	<i>195</i>
<i>Transdermal buprenorphine.....</i>	<i>195</i>
<i>Transdermal trans-capsaicin</i>	<i>195</i>
<i>Powder Injection Systems</i>	<i>196</i>
Intranasal delivery of analgesics	196
<i>Intranasal morphine</i>	<i>197</i>
<i>Intranasal morphine derivatives.....</i>	<i>197</i>
<i>Intranasal fentanyl</i>	<i>198</i>
<i>Intranasal buprenorphine</i>	<i>198</i>
<i>Intranasal ketamine</i>	<i>198</i>
<i>Intranasal ketorolac</i>	<i>199</i>
<i>Nasal formulations for migraine</i>	<i>199</i>
Oral spray formulations for migraine	199
Delivery of analgesics by inhalation	200
Buccal transmucosal and sublingual delivery of analgesics	201
<i>Application for cancer pain</i>	<i>201</i>
<i>Application for non-cancer pain.....</i>	<i>201</i>
Pumps for drug delivery in pain	202
<i>Patient controlled analgesia.....</i>	<i>202</i>
<i>Postoperative pain pumps</i>	<i>202</i>
<i>Chronogesic (sufentanil) Pain Therapy System.....</i>	<i>203</i>
<i>Spinal pumps for delivery of analgesics.....</i>	<i>204</i>
Spinal delivery of analgesics.....	204
Epidural administration of analgesics	205
<i>Epidural dexamethasone.....</i>	<i>205</i>
<i>Epidural etanercept</i>	<i>206</i>
<i>Epidural morphine</i>	<i>206</i>
Intrathecal administration of analgesics	206
<i>Intrathecal CGX1160</i>	<i>206</i>
<i>Intrathecal fadolmidine.....</i>	<i>206</i>
<i>Intrathecal lidocaine.....</i>	<i>207</i>
<i>Intrathecal neostigmine</i>	<i>207</i>
<i>Intrathecal non-NMDA antagonists</i>	<i>207</i>
<i>Intrathecal prostaglandin antagonists</i>	<i>207</i>
<i>Intrathecal resiniferatoxin</i>	<i>208</i>
<i>Intrathecal ziconotide</i>	<i>208</i>
<i>Concluding remarks on intrathecal delivery of analgesic agents</i>	<i>209</i>
Intracerebroventricular morphine for pain	209
Development of drug delivery systems for pain therapy	209
Delivery of analgesics to the CNS across the blood brain barrier	210
Drug delivery systems in clinical trials	210
6. Drug Development for Pain.....	213
Introduction.....	213
Drugs in development for pain	213

Current research goals	214
The ideal analgesic.....	214
Pain R & D goals in the pharmaceutical industry.....	214
Drug targets in the spinal cord	215
Drug targets in the brain	215
Molecular targets for analgesic drugs	215
Activation of P2X7 receptors.....	215
Adenosine receptor agonists.....	216
Alfa2-adrenergic receptor agonists	216
Anti-NGF strategies	216
Bradykinin antagonists	217
Cannabinoids.....	217
<i>Cannabinoid receptor agonists</i>	218
<i>Cannabidiol</i>	219
<i>Cannabinor</i>	220
<i>Nabilone</i>	220
Capsaicin and VR1 receptor-based analgesics	221
<i>Vanilloid (capsaicin) receptor antagonists</i>	221
<i>VR1 receptor agonists</i>	221
CCR2 receptor blockade	222
Cholecystokinin antagonists	222
Cholinergic receptor agonists.....	222
Conotoxins as analgesics	223
Corticotropin-releasing factor	224
FAAH inhibitors.....	224
<i>PF-3845</i>	225
<i>URB597</i>	225
Free radical scavengers as analgesics	225
<i>Superoxide dismutase mimetics</i>	226
GABA analogues	226
<i>Subtype-selective GABAergic drugs</i>	226
Glial cell line-derived neurotrophic factor	227
Glutamate receptor antagonists	227
<i>NMDA receptor modulation for neuropathic pain</i>	227
<i>Alternatives to direct blocking of NMDA receptors</i>	228
<i>Glycine antagonists</i>	228
<i>Metabotropic glutamate receptors</i>	228
Histogranin-like compounds for the management of pain	229
Ion channels as targets for analgesic drugs	229
<i>Acid-sensing ion channels as drug target</i>	229
<i>Calcium channel blockers</i>	230
<i>P2X ion channel receptor antagonists</i>	230
<i>Sodium channel modulation</i>	231
Mas-related GPCR agonists.....	231
Microsomal prostaglandin E synthase inhibitors.....	232
NAALADase inhibitors	233
Nerve growth factor antagonists	233
Newer COX inhibitors.....	233
<i>COX-3 inhibitors</i>	234
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	234
Neuropeptide receptor antagonists for improving the efficacy of opioids.....	234
Nicotinic acetylcholine receptors	234
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	235
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	235
Nitric oxide-based analgesics.....	236
<i>Nitric oxide-releasing NSAIDs</i>	236
<i>Pharmacology of NO-SAIDs</i>	237
<i>COX-inhibiting nitric oxide donors</i>	237
<i>NO-donating structures to extend life cycle of existing analgesics</i>	238
<i>Nitric oxide mimetics</i>	238
<i>Neuronal nitric oxide synthase inhibitors</i>	238
Norepinephrine transporter inhibition	238
Opioid peptide receptors ligands	239
<i>Opioids with unique receptor characteristics</i>	240
<i>Buprenorphine</i>	240
<i>Nociceptin</i>	240
<i>Tapentadol</i>	241
Opioid analgesics acting outside the CNS	241
<i>Opioid analgesics acting at peripheral receptors</i>	241
<i>Peripherally acting mu-opioid receptor agonists</i>	242
<i>Targeting of opioid peptide-containing immune cells</i>	242

<i>Advantages of peripherally selective opioid drugs</i>	242
Resolvins	243
Somatostatin analogs	243
Substance P and neurokinin receptor antagonists.....	243
Substance P-Saporin	244
Targeting prostanoid synthesis	244
Tetrodotoxin based analgesics	245
TRPV1 antagonists	245
<i>TRPV1 antagonists in clinical trials</i>	246
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	247
Tumor necrosis factor- α antagonists.....	247
Cell and gene therapies for pain	248
Cell therapy	248
<i>Implantation of chromaffin cells</i>	248
<i>Role of stem cells in management of pain</i>	249
<i>Implantation of astrocytes secreting enkephalin</i>	249
<i>Cells for delivery of antinociceptive molecules</i>	249
<i>Implantation of genetically engineered cells</i>	250
<i>Cell therapy for low back pain</i>	250
<i>Cell therapy for knee pain due to degenerative disorders</i>	251
<i>Cell therapy for peripheral neuropathic pain</i>	251
<i>Concluding remarks on cell therapy for pain</i>	251
Gene therapy	252
<i>Rationale of gene therapy for pain</i>	252
<i>Vectors for gene therapy of pain</i>	253
<i>Methods of gene delivery for pain</i>	253
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	254
<i>Gene delivery by intrathecal route</i>	254
<i>Gene transfer to the dorsal nerve roots</i>	255
<i>Gene therapy of peripheral neuropathy</i>	256
<i>Gene transfer by injections into the brain substance</i>	256
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	257
<i>Gene therapy for producing enkephalin to block pain signals</i>	257
<i>Targeting nuclear factor-κB</i>	258
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	258
<i>Antisense therapy for pain</i>	258
<i>RNAi-based approaches for pain therapy</i>	259
<i>Potential applications of gene therapy for management of pain</i>	260
<i>Concluding remarks about gene therapy for pain</i>	260
Preclinical development of pain drugs	261
NGF-blocking antibody.....	262
Prostatic acid phosphatase as a novel analgesic	262
Preclinical development of drugs for neuropathic pain.....	262
<i>5-HT receptor agonists</i>	263
<i>A-803467</i>	264
<i>AM1241</i>	264
<i>Artemin/Neuroblastin</i>	264
<i>Capsazepine</i>	265
<i>Central nACh receptor agonists</i>	265
<i>CGP 35024</i>	265
<i>Drugs that suppress glial activation</i>	266
<i>Erythropoietin</i>	266
Gene therapy for neuropathic pain	266
<i>NCX 8001</i>	267
<i>NR2B subtype NMDA receptor ligands</i>	267
<i>NW-1029</i>	268
<i>R116301</i>	268
<i>Targeting tumor necrosis factor</i>	268
Future targets for osteoarthritic pain	268
Pain drugs in clinical trials	269
Clinical trials of miscellaneous drugs for pain.....	269
<i>Alvimopan</i>	271
<i>Asimadoline</i>	271
<i>EN3202</i>	272
<i>Oxytrex</i>	272
Drugs in clinical trials for postsurgical pain	272
<i>Bicifadine</i>	273
<i>DepoMorphine</i>	274
Cox-2 inhibitors in clinical trials	274
Clinical trials of disease modifying therapies for arthritis	275
Drugs in clinical development for neuropathic pain	276

<i>Adenosine A1 agonists for neuropathic pain</i>	279
<i>Botulinum toxin type A</i>	279
<i>CNV1014802</i>	279
<i>CPL7075</i>	280
<i>D-amino acid oxidase inhibitors</i>	280
<i>Glyx-13</i>	280
<i>IP-751</i>	281
<i>Lacosamide</i>	281
<i>Oxcarbazepine</i>	281
<i>Perampanel</i>	282
<i>Ralfinamide</i>	282
<i>Retigabine</i>	282
<i>SB-509</i>	282
<i>SCP-1</i>	283
<i>TC-6499</i>	283
<i>Tebanicline</i>	283
<i>Tezampanel</i>	284
<i>Thalidomide</i>	284
<i>TRO19622</i>	284
<i>V3381 (indantadol)</i>	284
<i>XP-13512</i>	285
<i>Zonisamide</i>	285
Drug discovery and development for migraine.....	286
<i>Drugs in clinical development for migraine</i>	286
<i>Clinical development of preventive therapies for migraine</i>	289
Drug development for visceral pain.....	289

7. Legal and regulatory issues of pain management..... 291

Pain relief as a legal right	291
Pain relief and the WHO	291
Regulatory issues	291
Opioids and cannabinoids.....	291
DEA and use of opioids for pain relief in terminal care.....	291
FDA and COX-2 inhibitors.....	292
Legal issues of COX-2 inhibitors	293
Regulatory issues of opioid safety	293
Opioid misuse and regulatory agencies.....	293
FDA measures for safety of opioid use.....	293
Misuse of fentanyl.....	294

8. Pain Markets..... 295

Introduction	295
Epidemiological basis of pain markets	295
Cancer.....	296
Neuropathic pain.....	296
Trigeminal neuralgia.....	296
Arthritis.....	296
Backache.....	296
Migraine.....	297
Multiple sclerosis.....	297
Irritable bowel syndrome.....	297
Chronic pelvic pain.....	297
Chronic pain due to traumatic brain injury.....	297
Postsurgical pain.....	298
Economics of pain	298
Pain as a driver of healthcare costs.....	298
Disability and financial loss through pain.....	299
Pain markets based on painful conditions	299
The cancer pain market.....	299
The arthritis pain market.....	300
Postsurgical pain market.....	300
The backache market.....	300
The headache market.....	301
Neuropathic pain market.....	301
Fibromyalgia market.....	302
Pain markets based on drugs	302
Opioids.....	302
Nonsteroidal antiinflammatory drugs.....	303
Transdermal pain therapeutics.....	303
Anesthesia.....	303
Antiepileptic drugs as analgesics.....	304

Other drugs.....	304
Hospital vs retail share of pain market.....	304
<i>Hospital versus retail opioid market</i>	304
Devices for pain.....	304
Pain markets according to geographical areas.....	305
Cost effectiveness of various approaches	305
Unfulfilled R&D needs in pain therapy	306
Under treatment of pain.....	306
Unfulfilled needs in drug development for chronic pain	306
Strategies for developing pain markets	307
Finding alternatives to intrathecal administration for chronic pain	307
Development of other applications of analgesic drugs	307
Partnership of patients, pharmacists and companies.....	308
Factors that may influence future pain markets.....	308
Drivers of pain markets	308
Public surveys as indicators of impact of pain on people.....	309
Effect of regulatory reviews on markets for pain products	309
Novel versus older therapies for pain.....	310
9. Future of Pain Therapeutics.....	311
Introduction.....	311
Advances in the understanding of pain	311
Pathogenesis of chronic pain	311
Role of glia in neuropathic pain	311
Molecular and neurobiological techniques	312
Improved understanding of cancer pain	313
Advances in drug discovery and development for pain	313
Novel targets for drug discovery for pain.....	313
<i>PTH2 receptor</i>	313
<i>Modulators of endogenous cannabinoids</i>	314
Application of new technologies to pain therapeutics	314
<i>Application of nanobiotechnology to pain therapeutics</i>	315
<i>Technologies for the manufacture of analgesics</i>	316
Future trends and needs in pain management	316
Pain management in future healthcare systems	317
Systems biology approach to pain	317
Personalized pain management	318
Pharmacogenomics and pharmacogenetics of pain	319
Genetic mutations associated with reduced response to analgesics.....	320
Genetic mutations with loss of pain	320
Mechanism-specific management of pain	321
Preoperative testing to tailor postoperative analgesic requirements	321
Strategies for improving pain management	321
10. Companies Involved in Pain Therapeutics.....	323
Introduction.....	323
Profiles of companies.....	323
Collaborations.....	491
11. References.....	497

Tables

Table 1-1: Landmarks in the history of pain therapeutics	20
Table 1-2: Classification of pain	22
Table 1-3: Classification of neuropathic pain	24
Table 1-4: Classification of chronic cancer pain according to cause.....	25
Table 1-5: Percentage of patients with pain according to the type of cancer	26
Table 1-6: Key molecular elements of pain in the peripheral nervous system	48
Table 1-7: Key molecular elements of pain in the central nervous system	49
Table 2-1: IASP guidelines for the use of animals in pain studies	62
Table 2-2: Chronic pain as a manifestation of other diseases.....	63
Table 2-3: Recommendations for assessing patient satisfaction with pain management	68
Table 3-1: Classification of some currently used pain medications according to mechanism	75
Table 3-2: Drugs used for the treatment of pain	75
Table 3-3: Selective COX-2 inhibitors in clinical use for pain.....	77
Table 3-4: Antiepileptic drugs with analgesic effect	91
Table 3-5: Companies with products to deter abuse of opioids.....	102
Table 4-1: Non-pharmacological approaches to management of pain.....	108

Table 4-2: Companies involved in neuromodulation therapy for pain	114
Table 4-3: Reasons for the inadequate management of acute pain	116
Table 4-4: Causes of chronic backache	132
Table 4-5: Management of chronic pelvic pain	135
Table 4-6: Management of pain in cancer	135
Table 4-7: Definitions of tolerance, physiological dependence, withdrawal and addiction	142
Table 4-8: A simplified classification of headache	142
Table 4-9: Various methods for the management of migraine.....	143
Table 4-10: Management of neuropathic pain based on mechanism and diagnosis	153
Table 4-11: Management of central neuropathic pain	156
Table 4-12: Current management of peripheral diabetic neuropathy	159
Table 4-13: Treatment strategies for postherpetic neuralgia.....	161
Table 4-14: Management of complex regional pain syndrome.....	163
Table 4-15: Methods of treating phantom limb pain	165
Table 4-16: Treatment of chronic unexplained pain due to central sensitization	171
Table 4-17: Anti-itching therapies.....	172
Table 4-18: Suggested improvements in the management of pain	182
Table 5-1: A classification of drug delivery methods used in management of pain	185
Table 5-2: Selected marketed non-injection drug delivery systems for pain.....	189
Table 5-3: Spinal administration of drugs for pain	204
Table 5-4: Selected drug delivery systems for pain in clinical development	210
Table 6-1: Classification of drugs in development for pain.....	213
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics	218
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics	219
Table 6-4: NO-related therapies for pain.....	236
Table 6-5: Major opioids receptors and their ligands.....	239
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS	245
Table 6-7: Types of TRPV1 antagonists.....	246
Table 6-8: TRPV1 antagonists in clinical trials.....	246
Table 6-9: Experimental gene therapy approaches for relief of pain	254
Table 6-10: Selected preclinical approaches to pain therapy.....	261
Table 6-11: Selected preclinical drugs for neuropathic pain	262
Table 6-12: Selected clinical trials of miscellaneous drugs for pain	269
Table 6-13: Selected clinical trials of drugs for postsurgical pain	272
Table 6-14: COX-2 inhibitors in clinical development	274
Table 6-15: Disease modifying drugs for arthritis in clinical trials	275
Table 6-16: Clinical trials of drugs for neuropathic pain	276
Table 6-17: Selected drugs in clinical development for migraine	286
Table 6-18: Therapeutic targets for treating visceral pain	289
Table 8-1: Market values for various painful conditions 2011-2021	299
Table 8-2: Changes in market shares of drugs for neuropathic pain 2011-2021	301
Table 8-3: Markets for pain according to therapies 2011-2021	302
Table 8-4: Distribution of value of pain therapeutics in major markets 2011-2021	305
Table 8-5: Distribution of value of opioids in major pain markets 2011-2021.....	305
Table 8-6: Distribution of value of NSAIDs in major pain markets 2011-2021.....	305
Table 8-7: Strategies for developing pain markets	307
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	319
Table 10-1: Product pipeline of Adolor Corporation.....	329
Table 10-2: Selected collaborations in the area of pain management.....	491

Figures

Figure 1-1: Afferent pain pathways	28
Figure 1-2: Evolution of the gate control theory	30
Figure 1-3: The body self-neurometric.....	31
Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	49
Figure 1-5: Prostaglandin biosynthesis pathway	52
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	64
Figure 2-2: Pain intensity scales	65
Figure 4-1: The WHO step ladder for pain	136
Figure 4-2: An algorithm for the acute management of migraine	145
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	152
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	164
Figure 4-5: Algorithm for management of patients with chronic pain and depression	169
Figure 5-1: Powder Injection Systems	196
Figure 6-1: Attributes of the ideal analgesic	214
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain	257
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	306
Figure 9-1: Impact of new technologies on pain therapeutics	315
Figure 9-2: A scheme of personalized management of pain	318